27th April 2022
Consilium Strategic Communications advises Cambridge Innovation Capital on the closing of its $300 million Fund II
London, 27 April 2022; Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported Cambridge Innovation Capital on the closing of its oversubscribed second fund at £225million ($300 million).
Cambridge Innovation Capital is the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem. With Fund II, CIC now manages in excess of £500 million, giving it the scale to support its portfolio companies throughout their life cycle, providing investment capital as well as strategic and operational support.
“This fund close is a testament to CIC’s unique investment model, and the talented team at CIC. We would like to congratulate Andrew and the team on this successful fundraise and we are proud to have supported CIC to communicate its news globally,” said Mary-Jane Elliott, Founder and Managing Partner of Consilium Strategic Communications.
“The closing of Fund II is an important milestone for Cambridge Innovation Capital. The Cambridge ecosystem is reaching a concentration of research and innovation that I have only previously seen when working in Silicon Valley. We worked with Consilium on this key piece of news due to their experience and ability to dedicate time and resource to delivering a bespoke project. Hats off to them – they did a great job and are a pleasure to work with,” said Andrew Williamson, Managing Partner of CIC.
The Consilium team representing Cambridge Innovation Capital on the fund closing was Mary-Jane Elliott, Sukaina Virji, Andrew Stern and Jessica Pilling.
To view Cambridge Innovation Capital’s announcement, please visit www.cic.vc
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in both Europe and US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to
discrete specialist reputation management projects. For more information please see www.consilium-comms.com
About Cambridge Innovation Capital
Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category-leading deep tech and life sciences companies. CIC was founded to improve the success rate of businesses originating from the University of Cambridge and the broader Cambridge ecosystem, to encourage more academics and entrepreneurs from the area to build businesses. CIC currently manages in excess of £0.5 billion and has invested in around 40 companies. CIC is a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups. For more information, please visit www.cic.vc/, or follow on Twitter @cic_vc or LinkedIn.